- Home
- KINS vs CRBU Comparison
KINS vs CRBU Comparison
Compare KINS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KINS | CRBU |
|---|---|---|
| Founded | 1886 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.0M | 203.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KINS | CRBU |
|---|---|---|
| Price | $15.94 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 164.9K | ★ 1.2M |
| Earning Date | 03-05-2026 | 03-09-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | ★ 69.11 | N/A |
| EPS | ★ 2.26 | N/A |
| Revenue | ★ $198,583,138.00 | $9,295,000.00 |
| Revenue This Year | $37.94 | $0.22 |
| Revenue Next Year | $8.63 | $4.48 |
| P/E Ratio | $7.10 | ★ N/A |
| Revenue Growth | ★ 32.70 | N/A |
| 52 Week Low | $13.08 | $0.66 |
| 52 Week High | $22.40 | $3.54 |
Technical Indicators
Market Signals| Indicator | KINS | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 51.60 |
| Support Level | $15.80 | $1.45 |
| Resistance Level | $17.39 | $1.65 |
| Average True Range (ATR) | 0.59 | 0.11 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 50.71 | 63.89 |
Price Performance
Historical ComparisonAbout KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.